Option Care Health, Inc. research snapshot
OPCH AI stock analysis currently reads Option Care Health as the largest independent U.S. home and alternate-site infusion services provider, with TTM revenue near $5.69 billion, TTM net income near $209.6 million, and a business riding the long-term site-of-care shift from hospital to home. At the August 4, 2026 research cutoff, the latest verified intraday quote was $23.81 on August 3, 2026, market capitalization was about $3.57 billion on roughly 149.8 million shares after active buybacks, and the stock remains down about 25% year to date from its $31.86 opening. The July 29, 2026 Q2 report delivered adjusted EPS of $0.45 versus a $0.43 consensus and revenue of $1.44 billion up 1.9% year over year, while management narrowed FY2026 adjusted EPS guidance to $1.85 to $1.92 and reaffirmed revenue of $5.675 billion to $5.775 billion. The core debate is whether the post-earnings recovery from the June low near $18 to $20 reflects a genuine re-rating of a defensive healthcare services business, or whether reimbursement risk, CVS-related channel concerns flagged by Deutsche Bank, thin margins, and short interest near 8.7% of float justify continued caution. This page uses scenario analysis, not a certain price prediction, and it is informational research rather than investment advice.
Current price
$23.81
Market cap
$3.57 billion
AI score
66 / 100
Rating
Constructive hold: leading home infusion provider with improving momentum, a Q2 earnings beat, and a still modest valuation offset by thin margins and elevated short interest
Trend status
Recovering from the 52-week low area after a Q2 2026 earnings beat, but still down roughly 25% year to date from the $31.86 opening print
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Option Care Health is the largest independent provider of home and alternate-site infusion services in the U.S., administering injectable therapies through a nationwide pharmacy and nursing network serving all 50 states and Puerto Rico. | High |
| Moat | The moat comes from scale, geographic footprint, payer relationships, pharmacy infrastructure, nursing network, and regulatory compliance. It is a moderate moat because large hospital systems and national pharmacy chains could compete more aggressively, and the Deutsche Bank downgrade cited CVS-related channel pressure. | Medium |
| Management | CEO John C. Rademacher has emphasized 2026 strategic initiatives, operational execution, and shareholder returns, and the company repurchased $150 million of shares in Q2 2026. Insiders have net bought about $1.55 million in stock over the last three months with zero insider selling, a positive alignment signal. | Medium-high |
| Financial trend | FY2025 revenue was about $5.65 billion with net income near $207.6 million and net margins near 3.7%. Q2 2026 delivered revenue of $1.44 billion up 1.9% year over year and adjusted EPS of $0.45, beating consensus of $0.43. FY2026 adjusted EPS guidance was narrowed to $1.85 to $1.92 with revenue of $5.675 billion to $5.775 billion. | High |
| Valuation | At $23.81, OPCH trades at about 18x trailing EPS, 14.8x forward EPS, 0.63x price to sales, 2.7x to 2.9x book value, 11.7x price to free cash flow, and 11.5x EV/EBITDA. A verified three-scenario model produced a base case near $33, with downside if growth stalls or margins compress. | Medium-high for math, medium for forward assumptions |
| Technical trend | OPCH has recovered from the 52-week low of $18.01 to about $23.81, now trading above its 50-day moving average near $21.52 but below its 200-day moving average near $27.67. The stock is still down about 25% YTD and momentum is improving but not yet a confirmed uptrend. | Medium |
| Risk level | Risk is elevated for a mid-cap healthcare services company. Key risks include reimbursement policy changes by CMS and commercial payers, channel pressure tied to CVS noted in the Deutsche Bank downgrade, thin margins, competition from hospital systems and national pharmacies, and elevated short interest of about 8.73% of float. | Medium-high |
| AI confidence | High confidence for company filings, market-cap verification, revenue, net income, cash, debt, insider trading, and institutional holdings. Lower confidence for reimbursement policy trajectory, channel and competitive dynamics, volume growth, and margin expansion timing. | High data confidence |
| Investment certainty | Medium-Low certainty. The business model has defensive healthcare characteristics and a secular site-of-care shift tailwind, but the investment case depends on whether management can expand thin margins, navigate reimbursement and channel risk, and work down elevated short interest over time. | Medium-Low |
OPCH AI stock forecast
The OPCH AI stock forecast uses three scenarios based on forward EPS of about $1.85 and valuation multiples rather than a single deterministic price prediction. The base case assumes the company delivers on its FY2026 guidance of $1.85 to $1.92 adjusted EPS with gradual margin improvement. The bullish case depends on faster volume growth, better reimbursement, and margin expansion. The bearish case reflects reimbursement or channel cuts, margin compression, or operational setbacks.
$40 to $50
More likely if OPCH accelerates organic growth above 10%, expands operating margins through scale and cost efficiency, resolves the CVS-related channel concern, and the market applies a 20x forward PE multiple. The verified three-scenario model produced about $49 using 10% EPS growth and a 20x terminal multiple.
$28 to $36
More likely if OPCH tracks 6% EPS growth toward its FY2026 guidance midpoint near $1.89, holds steady revenue trends driven by the site-of-care shift, maintains current margins, and trades near 15x forward earnings. The verified model base case was about $33, consistent with the consensus analyst price target near $29.
$18 to $24
More likely if reimbursement pressure increases, channel dynamics worsen, margins stay compressed or shrink, volume growth decelerates, or the market assigns a lower 11x PE multiple reflecting lower growth expectations. The verified bear model produced about $20, only modestly below the recent low.
OPCH AI technical analysis
OPCH AI technical analysis starts from the $23.81 intraday quote on August 3, 2026. The stock has rebounded from the 52-week low of $18.01 after the July 29 Q2 beat and is now above its 50-day moving average near $21.52 but below its 200-day moving average near $27.67. The $21.50 to $22 zone is the first support, while resistance emerges near $24 to $25, then $27.67, and then the $30 to $32 area. Levels should be checked against Q3 2026 earnings expected around late October 2026, reimbursement updates, volume trends, and short interest changes.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $23.81 | Latest verified intraday quote for this page, reported for August 3, 2026. |
| First support | $21.50 to $22 | This zone covers the 50-day moving average near $21.52 and the recent consolidation area. A break below it would signal a pullback in the recovery. |
| Key support | $18 to $20 | This zone covers the 52-week low of $18.01 and the June consolidation area. A close below it would signal further downside risk. |
| Near resistance | $24 to $25 | The stock needs to reclaim and hold the $24 area first, then the $25 level, to confirm a short-term uptrend. |
| Key resistance | $27.67 to $30 | The 200-day moving average near $27.67 and the psychological $30 level represent the major recovery thresholds. |
| Major resistance | $31.86 to $36.80 | The YTD opening print of $31.86 and the 52-week high of $36.80 serve as the upper references for a full recovery case. |
| Momentum | RSI estimated near 63 | RSI near 63 shows improving momentum after the Q2 beat, but it is no longer in oversold territory, so chasing here carries more risk than near the June low. |
| Volume | Average volume about 2.5 million shares | Volume spiked to over 5 million shares around the July 29 earnings release, a sign of real buying interest. Sustained volume on up days would support the recovery. |
| Volatility | Beta 0.65 | OPCH has a lower beta than the broad market, but the YTD decline from $31.86 to the June low near $18 shows it can still draw down sharply during company-specific stress. |
| Invalidation | Break below $18 or guidance cut | A close below the $18.01 52-week low, a downward revision to EPS guidance, or an unfavorable reimbursement or channel policy change would weaken the base case. |
OPCH AI trading strategy
The OPCH AI trading strategy is a rules-based framework, not personalized advice. It should be monitored through live price, Q3 2026 earnings expected around late October 2026, volume trends, short interest changes, reimbursement and channel updates, and company guidance.
Wait for OPCH to hold above the $22 area with increasing volume and momentum, ideally after a retest of the 50-day moving average near $21.52. Confirmation improves if Q3 2026 results show sequential revenue growth in the low to mid single digits as guided and margin stability.
Reduce confidence if the stock breaks below $21.50, if volume expands on further down days, or if reimbursement, CVS channel, or competitive news turns negative.
Use pullbacks toward the $21.50 to $22 support zone as a watchlist condition only if the company reports stable operating trends, insider buying continues, and short interest does not spike further.
Do not treat the recovery low as an automatic floor. A break below the $18.01 52-week low with volume would suggest a new leg down. Position sizing should account for the elevated short interest and thin margins.
Track quarterly revenue growth, adjusted and GAAP EPS, gross and operating margins, free cash flow, net debt to EBITDA, organic volume growth, reimbursement and channel updates, insider buying or selling patterns, and the buyback pace.
A combination of shrinking margins, negative guidance revisions, rising short interest, insider selling, and a close below $18 would override any bullish chart setup.
Investment research summary
Option Care Health is paid to administer complex injectable therapies to patients in their homes rather than in hospitals. Payers and providers benefit from lower costs, and patients benefit from convenience and comfort, driving a secular shift toward alternate-site infusion.
The moat comes from national scale, a specialized infusion pharmacy and nursing network, payer contracts, regulatory know-how, and relationships with pharmaceutical manufacturers. The moat is not impenetrable because hospital systems and large pharmacy chains could invest to compete, and the Q2 cycle brought a CVS-related channel concern.
The thesis can fail if the Centers for Medicare and Medicaid Services (CMS) or commercial payers cut reimbursement rates for infused drugs, if channel or PBM dynamics compress volumes, if drug cost inflation compresses margins, if labor shortages increase nursing costs, if competition from hospital systems or pharmacies intensifies, or if the company takes on too much debt.
CEO John C. Rademacher has emphasized 2026 strategic initiatives, operational execution, and shareholder returns, with $150 million in Q2 buybacks and $170.5 million in the first half. The insider buying signal of about $1.55 million in net purchases over the last three months with zero sales is a constructive alignment indicator.
The long-term trend is favorable: the shift of infusion therapy from hospital to home settings is a multi-decade secular trend driven by cost containment, patient preference, and technology enabling remote care. This creates a durable tailwind for the home infusion industry.
The verified scenario model produced about $49 in the bull case, $33 in the base case, and $20 in the bear case using forward EPS near $1.85. At $23.81, the stock prices in a below-consensus outcome. The margin of safety depends on whether the company can grow EPS toward its $1.85 to $1.92 FY2026 guidance versus the slower trajectory already embedded in the price.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| OPCH price | $23.81 intraday on August 3, 2026, up about 3.4% on the day | StockAnalysis real-time quote | August 3, 2026 |
| Market capitalization | $3.57 billion, verified as $23.81 x 149.79 million shares with 0.10% deviation | financial_rigor.py market cap verification | August 3, 2026 |
| Shares outstanding | 149.79 million shares, down 5.70% year over year and 2.99% quarter over quarter on buybacks | StockAnalysis statistics page | August 3, 2026 |
| Revenue TTM | $5.69 billion, cross-validated across Yahoo Finance, StockAnalysis, and MarketBeat with 0.00% deviation | Yahoo Finance, StockAnalysis, MarketBeat | August 3, 2026 |
| Net income TTM | $209.58 million consensus, cross-validated against MarketBeat at $207.59 million with 0.95% deviation | Yahoo Finance, StockAnalysis, MarketBeat | August 3, 2026 |
| Q2 2026 earnings | Adjusted EPS $0.45, beating consensus of $0.43 by $0.02. Revenue of $1.44 billion up 1.9% year over year and above the $1.42 billion consensus. GAAP EPS $0.35. | MarketBeat earnings data and company press release | August 3, 2026 |
| FY2026 guidance | Adjusted EPS narrowed to $1.85 to $1.92 from $1.82 to $1.92, revenue reaffirmed at $5.675 billion to $5.775 billion, adjusted EBITDA of $480 million to $495 million, operating cash flow of at least $320 million. | Option Care Health Q2 2026 press release, July 29, 2026 | August 3, 2026 |
| Valuation and financial metrics | 18.0x trailing PE, 14.8x forward PE, 1.38 PEG, 0.63 price to sales, 2.7x to 2.9x price to book, 11.7x price to FCF, 11.5x EV/EBITDA, FCF yield about 8.5%, EV of $4.64 billion. | StockAnalysis statistics and MarketBeat | August 3, 2026 |
| Balance sheet and cash | Cash of $193.77 million at June 30, 2026, total debt near $1.27 billion, debt to equity about 0.9 to 1.0, stockholders equity of $1.26 billion. | Company 10-Q and StockAnalysis statistics page | August 3, 2026 |
| Analyst consensus and targets | Hold consensus from 14 analysts (7 buy, 6 hold, 1 sell). Average price target $29.92, high $39.00, low $22.00. Deutsche Bank downgraded to Hold with a $24 target on July 30, 2026 citing CVS-related concerns. | MarketBeat analyst forecasts | August 3, 2026 |
| Insider and institutional activity | About 1.7% insider ownership with roughly $1.55 million net insider buying over 3 months (zero sales). Institutional ownership about 98%. Short interest at 8.73% of float with 6.53 days to cover as of July 15, 2026. | MarketBeat insider and short interest data | August 3, 2026 |
| Technical indicators | 52-week range $18.01 to $36.80. Beta 0.65. 50-day moving average $21.52, 200-day moving average $27.67, RSI near 63, average volume about 2.5 million shares. YTD decline of roughly 25% from the $31.86 open. | StockAnalysis statistics and MarketBeat | August 3, 2026 |
This OPCH AI stock analysis page is an informational tool only and is not investment advice, tax advice, or a recommendation to buy or sell any security. Forecast ranges are scenarios based on available public data as of August 4, 2026 and may be wrong if financial results, reimbursement policies, channel or competitive dynamics, margins, management execution, or market conditions change. Home infusion services are subject to regulatory and reimbursement risk. Investing in mid-cap healthcare stocks carries risks including but not limited to margin pressure, regulatory changes, and market volatility.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
